Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753641 | 0.95 | SOS1 (0.42) | SOS1SOS2USP2CYP2D6 | |
| SCHEMBL1753460 | 0.93 | SOS1 (0.39) | SOS1SOS2USP2CYP1A2 | |
| SCHEMBL1753463 | 0.93 | SOS1 (0.39) | SOS1SOS2USP2 | |
| SCHEMBL1753876 | 0.87 | SOS1 (0.41) | SOS1SOS2 | |
| SCHEMBL1753869 | 0.86 | SOS1 (0.42) | SOS1SOS2 | |
| SCHEMBL16144786 | 0.85 | SOS1 (0.40) | SOS1SOS2 | |
| SCHEMBL24723696 | 0.83 | SOS1 (0.43) | SOS1SOS2 | |
| SCHEMBL1753680 | 0.80 | SOS1 (0.45) | SOS1SOS2 | |
| SCHEMBL15692485 | 0.79 | SOS1 (0.33) | SOS1SOS2 | |
| SCHEMBL23467579 | 0.79 | DRD4 (0.35) | SOS1SOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123991-A1 | TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123999-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-4289428-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Applied Pharmaceutical Science, Inc. (CN) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023064586-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2022261204-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| EP-3322706-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| WO-2018136661-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| US-20170252350-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
| WO-2017011776-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-9493474-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20140288042-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2014-09-25 | — | — | US | disclosed |
| EP-2102208-B1 | NOVEL SUBSTITUTED DIAZA SPIRO PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-23 | — | — | EP | disclosed |
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-8158643-B2 | Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
| US-7612056-B2 | schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pre-eclampsia, nociception, neuropathic pain, pancreatitis, neurogenic inflammation, asthma, chronic obstructive pulmonary disease (COPD) and urinary incontinence | JENSSEN PHARMACEUTICA N.V. (BE) | 2009-11-03 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20070254904-A1 | Substituted Diaza-Spiro-[4.5]-Decane Derivatives and Their Use as Neurokinin Antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170252350-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | SOS1 2822/4885SOS2 3022/4885USP2 1497/4885 |
| US-20140288042-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ2, KCNJ11, KCNK2 | SOS1 1117/4885SOS2 1178/4885USP2 4467/4885 |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | SOS1 4103/4885SOS2 3833/4885USP2 1538/4885 |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | MCHR1, MCHR2, MC1R | SOS1 1295/4885SOS2 3181/4885USP2 4764/4885 |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | SOS1 2459/4885SOS2 2500/4885USP2 3338/4885 |
| US-20070254904-A1 | Substituted Diaza-Spiro-[4.5]-Decane Derivatives and Their Use as Neurokinin Antagonists | NPSR1, PROKR2, PROKR1 | SOS1 1604/4885SOS2 1527/4885USP2 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.